Lyell Immunopharma Q2 net loss $63.9M, no revenue, cash $632.7M; Phase 1 data on track

Lyell Immunopharma, Inc.

2023-Q2 EPS reported -$0.52 revenue$92,000

Net loss of $63.9M for Q2 2023, compared to $36.3M in Q2 2022; non-GAAP net loss $45.6M vs $10.3M.
Revenue near zero vs $35.7M in prior year period, due to termination of GSK collaboration in Dec 2022.
Cash, cash equivalents and marketable securities $632.7M as of June 30, 2023; expected to fund operations into 2026.
Appointed Matt Lang as Chief Business Officer, also serving as Chief Legal Officer and Corporate Secretary.
Phase 1 trials LYL797 and LYL845 ongoing; initial data expected 2024; IND for LYL119 expected H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lyell Immunopharma, Inc. reported the quarter ended June 30, 2023 results: revenue approximately zero, net income net loss of $63.9 million.

Period: the quarter ended June 30, 2023
Revenue: approximately zero
Net income: net loss of $63.9 million
Result: reported results

Exact text from the filing

Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-028189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.